General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years - starting in the UAE and expanding into Saudi Arabia - and in so doing turned MEA into one of its growth centres. As the company plans to increase its presence in Egypt, he also discusses the opportunities presented by the country's current healthcare transformation.
The MEA region is indisputably becoming a growth hub for Ipsen
Bristol Myers Squibb’s Oscar Delgado outlines the firm’s successes in bringing innovative medicines to the Middle East and Africa in recent years, how its strategy plays out in an economically…
Based in Egypt, Medtronic Africa’s regional vice president, Eman Ali, speaks about the challenges of building a strategic roadmap and local capabilities for the entire African continent from the ground…
Building on a stellar career in pharma and medtech both in Egypt and internationally, Ahmed Ezz El-Din now serves as CEO of Cleopatra Hospitals Group, Egypt’s largest private hospital provider.…
Amgen has forged a solid position as one of the world’s largest independent biotechnology companies. With a market capitalisation of some USD 130 billion and 27 approved medicines, the US-based…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
See our Cookie Privacy Policy Here